TRACY TAYLOR: Open Payments
NPI 1740405711 · LONGVIEW, TX. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$4,546 in 241 payments from 14 companies in 2025. Trend: 2023 $2,908 · 2024 $3,550 · 2025 $4,546
Food & beverage: $4,546
| Company | Payments | Amount |
|---|---|---|
| Vanda Pharmaceuticals Inc. | 39 | $825 |
| Neurocrine BioSciences, Inc. | 40 | $763 |
| Teva Pharmaceuticals USA, Inc. | 45 | $659 |
| Otsuka America Pharmaceutical, Inc. | 21 | $446 |
| ABBVIE INC. | 17 | $379 |
| E.R. Squibb & Sons, L.L.C. | 23 | $364 |
| Alkermes, Inc. | 20 | $346 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 12 | $277 |
| Lundbeck LLC | 12 | $211 |
| Axsome Therapeutics, Inc. | 3 | $88 |
Products named: FANAPT, INGREZZA, REXULTI, VRAYLAR, COBENFY, AUSTEDO XR, UZEDY, CAPLYTA.
Industry payments across TX — which companies pay providers there.
